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Abstract
In the present study, a cell-penetrating peptide, the transactivating transcriptional factor (TAT) domain from HIV,
was linked to PEGylated multi-walled carbon nanotubes (MWCNTs) to develop a highly effective antitumor drug
delivery system. FITC was conjugated on MWCNTs-polyethylene glycol (PEG) and MWCNTs-PEG-TAT to provide
fluorescence signal for tracing the cellular uptake of the nanocarrier. After loaded with an anticancer agent,
doxorubicin (DOX) via π − π stacking interaction, the physicochemical characteristics, release profile and
biological evaluation of the obtained nano-sized drug carrier were investigated. The DOX loaded MWCNTs-PEG and
MWCNTs-PEG-TAT drug carriers both displayed appropriate particle size, excellent stability, high drug loading,
and pH-dependent drug release profile. Nevertheless, compared with DOX-MWCNTs-PEG, DOX-MWCNTs-PEG-TAT
showed improved cell internalization, intracellular distribution and potentiated anticancer efficacy due to the
TAT-mediated membrane translocation, endosomal escape and nuclear targeting. Furthermore, the therapeutic
efficacy of DOX was not compromised after being conjugated with MWCNTs-PEG-TAT and the proposed
nanocarrier was also confirmed to have a good biocompatibility. In conclusion, our results suggested that the
unique combination of TAT and MWCNTs as a multifunctional drug delivery system might be a powerful tool
for improved anticancer drug development.
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Background
During the last few decades, increasing attention has
been paid to multifunctional drug delivery systems using
nanotechnology to improve the overall therapeutic effi-
cacy of anticancer activity [1, 2]. Among all those systems,
carbon nanotubes (CNTs) are one of the most interesting
nanocarries currently under investigation. Ever since their
emergence on the nanoplatform, CNTs have shown great
promise as novel delivery systems due to their unprece-
dented advantages, such as ultralight weight, excellent
chemical and thermal stability [3], high drug-loading cap-
ability, and prolonged circulation time [4]. In particular,
CNTs have large surface area and internal cavity that
can be functionalized with various kinds of ligands and
filled with therapeutic agents to obtain synergistic effi-
cacy of antitumor activity. Doxorubicin (DOX), a DNA
interacting drug, has been widely used as the drug of
choice in anticancer therapy. However, its clinical utility
was hampered by cumulative, dose-limiting cardiotoxicity,
myelosuppression, and the developmental drug resistance
[5]. As a result, attempts were made to incorporate DOX
into CNTs via π-π stacking to improve therapeutic out-
comes [6–8]. Moreover, CNT-based drug delivery systems
have also shown great prospect in other various experi-
ments such as delivery of paclitaxel [9] and small inter-
fering RNA [10].
Nevertheless, the application of CNTs in medicine
and biology is hampered by their poor solubility in
aqueous solutions. Therefore, surface modifications of
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CNTs including covalent attachment and non-covalent
attachment have been used to conquer a lack of solubility
and to improve their biocompatibility [11]. Among all the
modifications, the covalent link between polyethylene gly-
col (PEG) and CNTs has lead to stable dispersion and bio-
compatibility in various biological environments [12].
In order to further improve the intracellular transloca-
tion process across the plasma membrane for an enhanced
therapeutic effect, a promising approach—the use of cell-
penetrating peptides (CPPs) is put forward. CCPs are a
family of positively charged short peptides that might be a
promising candidate for drug delivery since they were
demonstrated to be able to transport attached macromole-
cules from extracellular space through the cell membrane
into cytoplasm effectively in various investigations [13].
The transactivating transcriptional factor (TAT), one of
the potential CPPs, is a cationic peptide derived from
the human immunodeficiency virus type 1 (HIV-1) [14]. A
number of studies have used TAT to transport intracellular
cargoes such as liposomes [15], polymers [16], quantum
dots [17], micelles [18], and nanoparticles [19]. Moreover,
TAT was also found to be capable of taking the DOX-
loaded micelles not only into the cells but also to the
nucleus [18]. And strategies like PEGylation [20] or
charge neutralization [21] have been used to prevent
TAT-modified nanocarriers from interacting with non-
target tissues and prolong their circulation time in the
bloodstream. In addition, TAT has also been shown to
exhibit good biocompatibility [22]. However, in spite of
the prominence of TAT in the nanotechnology areas,
exploration of its application in drug delivery is still at
a very early stage. Especially, few papers have addressed
the use of CNTs combined with TAT peptide in the field
of drug delivery and anticancer therapy.
In this study, a novel drug delivery system employing
PEGylated multi-walled carbon nanotubes (MWCNTs) was
developed with the combination of a cell-penetrating
peptide TAT. The synthetic scheme is shown in Fig. 1.
Briefly, the raw MWCNTs were first oxidized and the ob-
tained oxidized MWCNTs were then functionalized by 1,2-
distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy
poly(ethylene-glycol)-2000 (DSPE-PEG2000) or 1,2-istear-
oyl-sn-glycero-3-phosphoethanolamine-N-[poly-(ethylene
glycol)-2000]-maleimide (DSPE-PEG2000-Mal). After
that, the TAT peptide was conjugated to the maleimide
groups of DSPE-PEG2000-Mal by an addition reaction
with the sulfhydryl groups of cysteine in TAT. Then,
the obtained MWCNTs-PEG and MWCNTs-PEG-TAT
were labeled with fluorescein isothiocyanate (FITC) re-
spectively to investigate their intracellular distribution.
After being loaded with DOX, the physicochemical charac-
teristics and release profile of the obtained nano-sized drug
carrier were investigated. Then, the cellular uptake, intra-
cellular localization, anticancer activity, and apoptosis-
inducing capability of the DOX-loaded MWCNTs-PEG
and MWCNTs-PEG-TAT were studied in vitro.
Methods
Materials
Raw multi-walled carbon nanotubes (MWCNTs) were ob-
tained from Chengdu Organic Chemicals Co. Ltd., with the
diameter ranging from 10 to 20 nm and the length ranging
from 10 to 30 μm (95 % purity in MWCNTs). TAT
(Cys-Tyr-Gly-Arg-Lys-Lys–Arg-Arg-Gln-Arg-Arg-Arg)





Mal) were purchased from Laysan Bio Inc. (Arab,
Alabama, USA). Doxorubicin (DOX) hydrochloride was
obtained from Beijing Huafeng United Technology Co.
(Peking, China). Fluorescein isothiocyanate (FITC) was
purchased from Sigma-Aldrich (St. Louis, MO, USA).
2-(4-Amidinophenyl)-6-indolecarbamidine dihydrochloride
(DAPI) and Annexin V-FITC/PI apoptosis detection kit
Fig. 1 A schematic diagram of the steps involved in preparing DOX-MWCNTs-PEG-TAT for drug delivery
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was obtained from KeyGEN Biotech Co., Ltd. (Shanghai,
China). Dulbecco’s modified Eagle’s medium (DMEM),
fetal bovine serum (FBS), penicillin-streptomycin solution,
and trypsin-EDTA solution were purchased from Hyclone
(Logan, Utah, USA). The human osteosarcoma (MG63)
cells and human umbilical vein endothelial (HUVEC) cells
were supplied by the State Key Laboratory of Oral Diseases
(Chengdu, China).
Preparation and Characterization of MWCNTs
The pristine MWCNTs were initially purified and treated
with strong oxidizing acid following the previous method
[8]. Briefly, raw MWCNTs were added to a mixture of
concentrated nitric acid and sulfuric acid (V/V = 1:3) for
8 h. After that, the oxidized MWCNTs solution was
washed thoroughly with purified water for several times
and filtered with polytetrafluoroethylene (PTFE) mem-
brane until the pH value reached neutral. The acquired
oxidized MWCNTs were then functionalized by DSPE-
PEG2000 or DSPE-PEG2000-Mal according to the pre-
viously reported method [23]. Briefly, 10 mg oxidized
MWCNTs and DSPE-PEG2000-Mal were dispersed in
10 ml purified water and then sonicated for 2 h at room
temperature. The obtained complex (MWCNTs-PEG-
Mal) was then purified by Millipore ultrafiltration tube
(MWCO = 100 kDa) and dried in vacuum at 60 °C and
collected for further use. The MWCNTs-PEG was pre-
pared as MWCNTs-PEG-Mal with the addition of
DSPE-PEG2000 instead of DSPE-PEG2000-Mal.
The microstructures and surface morphology of oxi-
dized MWCNTs were characterized by scanning electron
microscopy (SEM) (Inspect F50, OR, USA). The fourier
transform infrared (FTIR) spectroscopy (Nicolet 6700,
WI, USA) was performed to study the functional groups
of pristine and oxidized MWCNTs. The Raman spectra
(LabRAM HR-800, Longjumeau, France) of nanotubes
were recorded with a laser at an excitation wavelength of
632.8 nm. The purity of MWCNTs was investigated by
thermogravimetric analysis (TGA) (STA 449/C Jupiter,
Germany).
Conjugation of TAT to DSPE-PEG2000-Mal
The MWCNTs-PEG-Mal was redispersed in PBS and
mixed with TAT. After overnight reaction, unbounded
excess TAT was removed by Millipore ultrafiltration
tube (MWCO = 100 kDa). Then, the resulting complex
(MWCNTs-PEG-TAT) was resuspended and stored at
4 °C for further use. MWCNTs, MWCNTs-PEG,
MWCNTs-PEG-Mal, and MWCNTs-PEG-TAT were
characterized by 1H-nuclear magnetic resonance (1H-
NMR) spectroscopy (Bruker, DRX, USA) at 400 MHz
with D2O as a solvent.
FITC Labeling of MWCNTs-PEG-TAT
One milligram per milliliter FITC in dimethyl sulfoxide
(DMF) was slowly added to 1 mg/ml MWCNTs-PEG-
TAT solution. The mixture was then sonicated in dark
for 2 h. Unbounded excess FITC was removed by ultra-
filtration (MWCO= 100 kDa) and washed thoroughly
with water (over 10 times) until the filtrate becomes
color free. The FITC-labeled MWCNTs-PEG-TAT (FITC-
MWCNTs-PEG-TAT) was redispersed in PBS (pH 7.4) and
stored at 4 °C in the dark. The FITC-labeled MWCNTs-
PEG (FITC-MWCNTs-PEG) was prepared as above with
MWCNTs-PEG instead of MWCNTs-PEG-TAT. Then,
the percentages of DSPE-PEG2000, DSPE-PEG2000-
Mal, TAT, and FITC linked to MWCNTs were quantified
by TGA (STA 449/C Jupiter, Germany) with a heating rate
of 10 °C/min from 30 to 800 °C, respectively.
DOX Loaded onto MWCNTs-PEG-TAT
DOX loaded onto MWCNTs-PEG-TAT was performed
as follows: 10 mg MWCNTs-PEG-TAT was dispersed in
PBS (pH 9.0) [6, 7]. Then, 10 mg DOX was slowly added
into the MWCNTs-PEG-TAT solution and sonicated for
2 h in a dark environment. Unbounded excess DOX was
removed by ultrafiltration tube (MWCO= 100 kDa) and
washed thoroughly with purified water (over 10 times)
until the filtrate becomes color free. The DOX-loaded
MWCNT-PEG-TAT (DOX-MWCNTs-PEG-TAT) was
resuspended in PBS (pH 7.4) and stored at 4 °C in dark-
ness. The unbounded DOX was measured at an absorb-
ance of 490 nm by microplate reader (MK3, Thermo,
USA). The calibration curve was also recorded under
the same conditions, allowing the amount of unbounded
DOX to be calculated. The DOX-loaded MWCNTs-PEG
(DOX-MWCNTs-PEG) was prepared as above with
MWCNTs-PEG instead of MWCNTs-PEG-TAT. Then,
the UV-Vis absorption spectra of MWCNTs-PEG,
MWCNTs-PEG-TAT, free DOX, DOX-MWCNTs-PEG,
and DOX-MWCNTs-PEG-TAT were measured to verify
the loading of DOX onto MWCNTs by a UV-Vis spectro-
photometer (UV-3600, SHIMADZU, Kyoto, Japan). The
DOX loading efficiency (DL%) was calculated using the
following formula:
DL% ¼Weight of loaded DOX‐Weight of free DOX
Weight of loaded DOX
 100%
Particle Size and Zeta Potential
The mean particle size and zeta potential of MWCNTs-
PEG, MWCNTs-PEG-TAT, DOX-MWCNTs-PEG, and
DOX-MWCNTs-PEG-TAT were measured by a Malvern
Zetasizer APS ZEN3600 instrument (Malvern Instruments
Ltd., UK) at 25 °C.
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In Vitro Drug Release of DOX
DOX release behaviors from MWCNT complexes were
investigated according to the previously reported method
[7]. Briefly, DOX-MWCNTs-PEG and DOX-MWCNTs-
PEG-TAT conjugates were studied in PBS (pH 5.3 and
pH 7.4) as release medium. The MWCNT conjugates
were filled in dialysis membrane (MWCO = 1 k Da) and
then immersed in 200 ml of PBS with stirring at 100 rpm
at 37 °C in the dark. At definite time points, 2 ml of the
medium was withdrawn and equivalent volumes of PBS
were replaced. The concentration of released DOX was
estimated by microplate reader.
Intracellular Tracking of FITC-MWCNTs-PEG-TAT
MG63 and HUVEC cells were plated in 6-well plates,
with the cells being seeded for 24 h before incubation.
Then, the cells were incubated in DMEM for 30 min and
treated with FITC-MWCNTs-PEG or FITC-MWCNTs-
PEG-TAT at MWCNT concentration of 20 μg/ml for 2 h.
After that, cells were washed with PBS three times
followed by soaking for 15 min in 4 % paraformalde-
hyde and washed with PBS. The nuclei were stained
with DAPI according to the operation manuals. The
stained cells were immediately observed using a fluor-
escence microscope (TE 2000-U, Nikon, Japan).
Intracellular Distribution of DOX-MWCNTs-PEG-TAT
MG63 and HUVEC cells were first cultured overnight to
allow attachment. Then, cells were incubated with free
DOX, DOX-MWCNTs-PEG and DOX-MWCNTs-PEG-
TAT at DOX concentration of 10 μg/ml for 2 h at 37 °C
in DMEM respectively. After incubation, the cells were
washed repeatedly with PBS three times followed by
soaking for 15 min in 4 % paraformaldehyde and washed
with PBS three times. The nuclei were stained with
DAPI according to the operation manuals. The stained
cells were then observed by a fluorescence microscope.
In Vitro Cytotoxicity Assay
MG63 cells and HUVEC cells were used to evaluate the
cytotoxicity of MWCNTs-PEG and MWCNTs-PEG-TAT
using the CCK-8 cell viability assay. Briefly, cells were
seeded in 96-well plates with a density of 20,000 cells/well
and allowed to adhere for 24 h prior to assay. Then, the
cells were treated with MWCNTs-PEG or MWCNTs-
PEG-TAT in culture medium for another 24 h. Subse-
quently, the culture medium was removed and replaced
by 100 μl of fresh medium and 10 μl of CCK-8 solution
and incubated for 2 h. Then, the OD value at 450 nm was
detected using a microplate reader. Furthermore, the cell
morphology of MG63 and HUVEC cells treated with
MWCNTs-PEG or MWCNTs-PEG-TAT for 24 h at
MWCNTconcentration of 50 μg/ml was observed by light
microscopy (Olympus IX, Japan).
The cytotoxicities of free DOX, DOX-MWCNTs-PEG,
and DOX-MWCNTs-PEG-TAT were also investigated by
the CCK-8 cell viability assay as above using MG63 cells.
Apoptosis Study
To study the apoptosis-inducing capability of DOX-
MWCNTs-PEG-TAT, MG63 cells were incubated with
10 μg/ml DOX-MWCNTs-PEG-TAT for 2, 8, 24, and
72 h at 37 °C in DMEM, respectively. After incubation,
the cells were washed repeatedly with sterilized PBS
and analyzed by fluorescence microscopy.
Quantitative analysis was performed using Annexin V-
FITC/PI double staining. Briefly, MG63 cells were seeded
at a density of 5 × 105 cells in 6-well plates and incubated
overnight before treatment. Then, the MG63 cells were
treated with 10 μg/ml DOX-MWCNTs-PEG-TAT for 2, 8,
24, and 72 h, respectively. After that, the cells were trypsi-
nized, washed with cold PBS, suspended in 400 μl of bind-
ing buffer, and stained with 5 μl Annexin V-FITC for
15 min and 5 μl propidium iodide (PI) for 5 min at 4 °C in
the dark. At the end of the treatment, the cells were ana-
lyzed by a flow cytometer (Beckman Coulter, Fullerton,
CA, USA).
Statistical Analysis
The obtained results were expressed as mean ± standard
deviation (SD) of triplicate. The statistical analysis was an-
alyzed using one-way ANOVA. A probability of P < 0.05
was considered statistically significant.
Results
Characterization of MWCNTs
The morphology of the oxidized MWCNTs was charac-
terized by SEM (Fig. 2a). The results showed that the
length of oxidized MWCNTs decreased apparently com-
pared with the raw MWCNTs (10 to 30 μm). The FTIR
spectra of raw MWCNTs and oxidized MWCNTs were
shown in Fig. 2b. The peaks at 1575.24 and 3423.62 cm−1
shown in both spectra were ascribed to the presence
of carbon residue on the CNT surface and O–H
stretching vibration, respectively. The characteristic
peak at 1725.18 cm−1 indicated the introduction of
carboxylic groups of oxidized MWCNTs, which was
extraordinarily weak in raw MWCNTs. The Raman
spectra of raw and oxidized MWCNTs were shown
in Fig. 2c. As indicated in the graph, raw MWCNTs
showed the Raman shift at 1329.72 and at 1579.76 cm–1,
which corresponds to the D band (disorder-induced
bands) and G band (graphite-like modes), respectively
[24]. However, the D band was shifted to 1334.49 and
G band to 1598.37 cm–1 after the carboxylation of
MWCNTs. To quantify the concentration of carboxylic
groups present on the surface of CNTs, thermogravimetric
analysis (TGA) of was also conducted under nitrogen
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atmosphere. It is clear that the weight loss of oxidized
MWCNTs is only about 3.2 % at the inflection point
(800 °C), while the oxidized MWCNTs has a weight loss
of 11.9 % (Fig. 2d).
Synthesis and Characterization of MWCNT Composites
The scheme of MWCNTs-PEG-TAT was shown in Fig. 1,
and the structure of the resulting complex was verified
by 1H NMR. As illustrated in Fig. 3a, the characteristic
resonance peak of 4.700 ppm was the solvent residual
peak. The characteristic peaks of PEG (3.613 ppm) and
Mal (6.783 ppm) shown in Fig. 3b,c, respectively, indicated
the successful synthesis of MWCNTs-PEG and MWCNTs-
PEG-Mal. After conjugation of TAT peptide to MWCNTs-
PEG-Mal, two characteristic peaks at 6.768 ppm (signal a)
and 7.091 ppm (signal b) were observed in Fig. 3d.
TGA was used to quantitatively analyze the percent-
ages of DSPE-PEG2000, DSPE-PEG2000-Mal, TAT, and
FITC linked onto the surface of MWCNTs, respectively.
As presented from Fig. 4a, DSPE-PEG2000 has 100 %
weight loss at the temperature of 438 °C, which could be
selected as the inflection point to calculate the weight losses
of MWCNTs after different modifications [25]. It could
be seen that at this inflection point (438 °C), oxidized
MWCNTs, MWCNTs-PEG, and FITC-MWCNTs-PEG
had weight losses of 8, 49, and 55 %, respectively.
Therefore, by subtracting the weight loss of unmodified
oxidized MWCNTs and MWCNTs-PEG, the conjugating
percentages of DSPE-PEG2000 and FITC were estimated
to be 41 and 6 %, respectively. Similarly, in the case of
FITC-MWCNTs-PEG-TAT composite (Fig. 4b), as oxi-
dized MWCNTs, MWCNTs-PEG-Mal, MWCNTs-PEG-
TAT, and FITC-MWCNTs-PEG-TAT had weight losses of
8, 55, 59, and 64 %, respectively, at the inflection point
(456 °C), the grafting percentages of DSPE-PEG2000-Mal,
TAT, and FITC could be estimated to be 47, 4, and 5 %,
respectively.
DOX Loading onto MWCNTs-PEG-TAT
DOX loading could be monitored by UV-Vis absorption
spectroscopy because DOX in water displays two main
characteristic absorptions at around 490 and 232 nm. As
shown in Fig. 4c, like free DOX, DOX-MWCNTs-PEG,
and DOX-MWCNTs-PEG-TAT also showed that these
two absorption peaks after conjugated with DOX when the
pH is 9.0, while MWCNTs-PEG and MWCNTs-PEG-TAT
appeared no peaks in the corresponding areas. Moreover,
DOX-MWCNTs-PEG and DOX-MWCNTs-PEG-TAT pre-
pared in this study exhibited drug-loading efficiency of 97.3
and 98.2 %, respectively (Table 1).
In this study, the average particle size of DOX-
MWCNTs-PEG and DOX-MWCNTs-PEG-TAT were
found to be 135.24 and 145.24 nm, respectively (Table 1).
Moreover, the two complexes had low polydispersity
Fig. 2 a The SEM image of oxidized MWCNTs. b The FTIR spectra of raw MWCNTs and oxidized MWCNTs. c The Raman spectra of raw MWCNTs
and oxidized MWCNTs. d The TGA results of raw MWCNTs and oxidized MWCNTs in nitrogen atmosphere
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indexes (PDIs) of 0.290 and 0.339, respectively (Table 1),
indicating homogeneity in their dispersion state. The
zeta potentials of MWCNTs-PEG, MWCNTs-PEG-TAT,
DOX-MWCNTs-PEG, and DOX-MWCNTs-PEG-TAT
were found to be −8.46, −9.03, −3.53, and −4.96 mV, re-
spectively (Table 1).
In Vitro Drug Release of DOX
The results of in vitro DOX release from DOX-MWCNTs-
PEG and DOX-MWCNTs-PEG-TAT at 37 °C in PBS at
pH 7.4 and 5.5 were presented in Fig. 4d. The drug release
curves showed that the two complexes displayed similar
accumulative release curves. A slow and controlled re-
lease manner could be seen at pH 7.4, to the extent of
nearly 30 % in 72 h, while a significant faster release
was observed in pH 5.5, with the accumulative release
achieved high percentage of above 80 % within the
same period.
Intracellular Tracking of FITC-Labeled MWCNTs-PEG-TAT
Uptake of FITC-MWCNTs-PEG and FITC-MWCNTs-
PEG-TAT by MG63 and HUVEC cells were examined.
Fluorescence microscopy was applied to track the intra-
cellular distribution of the FITC-labeled MWCNTs-PEG
and MWCNTs-PEG-TAT inside cells. Figure 5 showed
the fluorescent distribution of FITC-MWCNTs-PEG and
FITC-MWCNTs-PEG-TAT in MG63 and HUVEC cells,
respectively. The green fluorescence indicated the distri-
bution of FITC-MWCNTs-PEG or FITC-MWCNTs-PEG-
TAT, and the blue fluorescence indicated the nuclei
stained by DAPI. Both in MG63 and HUVEC cells, the
FITC fluorescence was significantly higher in cells in-
cubated with FITC-MWCNTs-PEG-TAT than that of
FITC-MWCNTs-PEG.
Cellular Uptake and Intracellular Distribution of
DOX-MWCNTs-PEG-TAT
In order to further investigate the role of TAT peptide and
the intracellular and intranuclear behavior of MWCNTs-
PEG-TAT after drug loading, the free DOX, DOX-
MWCNTs-PEG, and DOX-MWCNTs-PEG-TAT were
incubated with MG63 and HUVEC cells and analyzed
by fluorescence microscopy since the red fluorescence
of the DOX and the blue fluorescence of the DAPI
enabled the visualization of the cellular uptake and
Fig. 3 The 1H NMR spectra of a MWCNTs, b MWCNTs-PEG, c MWCNTs-PEG-Mal, and d MWCNTs-PEG-TAT
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intracellular distribution of the DOX and DOX-loaded
MWCNT complexes. As shown in Fig. 6, DOX accumu-
lated in the perinuclear region and cell nuclei of MG63
and HUVEC cells following 2-h incubation with free
DOX. However, the red fluorescence of DOX in the
DOX-MWCNTs-PEG and DOX-MWCNTs-PEG-TAT
complexes spread all over the cells, primarily in the cyto-
plasm with a small amount in the nuclei.
Moreover, in contrast to the very slight red fluores-
cence in DOX-MWCNTs-PEG, DOX-MWCNTs-PEG-
TAT exhibited much stronger red fluorescence signals
inside MG63 and HUVEC cells and displayed a more
diffuse distribution, indicating that the TAT conjugated
nanotubes were taken up more efficiently into MG63
and HUVEC cells.
In Vitro Cytotoxicity Assay
As shown in Fig. 7, MG63 and HUVEC cells continuously
incubated with MWCNTs-PEG and MWCNTs-PEG-TAT
for 24 h showed no detectable differences in cell morph-
ology. Moreover, the quantitative studies examining the
viability of these treated cells by the CCK-8 assay also
showed that the cell viability all remained above 90 % at
different concentrations, and there were no significant dif-
ferences between MWCNTs-PEG and MWCNTs-PEG-
TAT at any of the given concentrations (Fig. 8). Therefore,
these results proved good biocompatibility and biological
safety of MWCNTs-PEG and MWCNTs-PEG-TAT.
After being loaded with DOX, the cytotoxicity assay
towards MG63 cells was also conducted to evaluate the
antitumor activity of the drug-loaded MWCNTs and the
Table 1 Physiochemical characterization of different MWCNTs complexes
Group Particle size (nm) Polydispersity index Zeta potential (mV) DOX loading efficiency (%)
MWCNTs-PEG 89.39 0.343 −8.46 –
MWCNTs-PEG-TAT 96.26 0.394 −9.03 –
DOX-MWCNTs-PEG 135.24 0.290 −3.53 97.3
DOX-MWCNTs-PEG-TAT 145.24 0.339 −4.96 98.2
Fig. 4 a The TGA curves of oxidized MWCNTs, MWCNTs-PEG, FITC-MWCNTs-PEG, and DSPE-PEG2000, respectively. b The TGA curves of oxidized
MWCNTs, MWCNTs-PEG-Mal, MWCNTs-PEG-TAT, FITC-MWCNTs-PEG-TAT, and DSPE-PEG2000-Mal, respectively. c UV-Vis absorption spectra of DOX
and different MWCNTs complexes. d Drug release of DOX loaded MWCNTs-PEG and MWCNTs-PEG-TAT under different pH
Hu et al. Nanoscale Research Letters  (2016) 11:452 Page 7 of 14
results were shown in Fig. 9. The IC50 (the concentra-
tion of drug resulting in 50 % cell killing) values of
free DOX, DOX-MWCNTs-PEG, and DOX-MWCNTs-
PEG-TAT were 43.38 ± 1.08, 59.81 ± 1.15, and 46.20 ±
2.33 μg/ml, respectively.
Apoptosis Study
To study the apoptosis-inducing capability of DOX-
MWCNTs-PEG-TAT, the MG63 cell morphology change
and intracellular localization of DOX after treatment for
2, 8, 24, and 72 h were recorded respectively by the fluor-
escence images. As shown in Fig. 10, DOX-MWCNTs-
PEG-TAT conjugates were efficiently taken up by MG63
cells and rapidly localized in the cytoplasm and nucleus
within 2 h (Fig. 10a) with no detectable differences in cell
morphology. However, after 8 h (Fig. 10b), more DOX
accumulated in the perinuclear region and cell nuclei and
induced appreciable cell morphology changes, which
was indicative of the fact that the cells had undergone
apoptosis. After 24-h (Fig. 10c) incubation with DOX-
MWCNTs-PEG-TAT, nearly all DOX was observed in
the nuclei and the cancer cells underwent extensive
apoptosis, while after 72 h (Fig. 10d), nearly all cells
died and no cell morphology could be observed.
In order to further study the cell apoptosis-inducing
capability of DOX-MWCNTs-PEG-TAT, quantitative ana-
lysis was performed by staining with Annexin V FITC and
PI in MG63 cancer cells. The scatter plot has four quad-
rants: viable cells (Annexin V− PI−, Q4), early apoptotic
cells (Annexin V+ PI−, Q3), late apoptotic cells (Annexin
V+ PI+, Q2), and necrotic cells (Annexin V− PI+, Q1). As
seen in Fig. 11, after incubation with 10 μg/ml DOX-
MWCNTs-PEG-TAT for 2 h, only a small number of
apoptotic cells were observed. While after 8 h, approxi-
mately 13.0 % of cells were in early apoptosis stage and
6.67 % of cells were in late apoptosis stage. After 24 h of
incubation, up to 31.34 % cancer cells underwent either
early apoptosis or late apoptosis. As expected, after 72 h,
Fig. 5 Intracellular fluorescence distribution in MG63 and HUVEC cells after incubated with FITC-MWCNTs-PEG or FITC-MWCNTs-PEG-TAT at MWCNTs
concentration of 20 μg/ml for 2 h.
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most MG63 cells underwent apoptosis or necrosis, with
92.08 % of cells observed in the Annexin V positive or PI
positive quadrants (Q1 +Q2 +Q3).
Discussion
The surface of CNTs plays a vital role in the research
and development of drug delivery system. As raw nano-
tubes disperse poorly in aqueous solutions and often are
too long to be able to enter most cells and may be toxic,
techniques such as oxidation are employed to introduce
the hydrophilic functional groups at the side wall of the
CNTs via strong oxidizing acid method [8]. In this
study, the carboxylic groups were generated onto the
MWCNTs surface by the mixed acid reflux and the oxi-
dized MWCNTs were verified by FTIR, Raman spectra,
and TGA. The characteristic peak at 1725.18 cm−1 in
the FTIR spectrum indicated the introduction of car-
boxylic groups of oxidized MWCNTs (Fig. 2b). More-
over, Raman spectroscopy was not only able to give the
information about the hybridization state and defect
concentration of the nanotubes but also could offer in-
formation about the slight structural changes of the
nanotubes [26]. The weight loss of oxidized MWCNTs
shown in the TGA spectrum was partly because water
Fig. 6 Fluorescence images of MG63 and HUVEC cells incubated with free DOX, DOX-MWCNTs-PEG, and DOX-MWCNTs-PEG-TAT for 2 h at DOX
concentration of 10 μg/ml
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is absorbed from the air, demonstrating the highly hygro-
scopic nature of the oxidized nanotubes, and partly attrib-
uted to the consumption of carboxylic groups [27, 28].
Altogether, these results demonstrated the presence of
carboxylic acid groups at the surface of the oxidized
MWCNTs, which would not only conquer the poor solubil-
ity and improve the biocompatibility of oxidized MWCNTs
but also contribute to the subsequent PEG grafting.
The 1H NMR results confirmed the successful synthesis
of MWCNTs-PEG-TAT. As the maleimide groups could
selectively undergo an addition reaction with sulfhydryl
groups [29], the DSPE-PEG-Mal conjugate would be able
to react with cysteine in TAT and form covalent bonding.
Moreover, due to the influence of hydroxyl on the ben-
zene ring in tyrosine of TAT peptide, the proton in the
ortho-position and meso-position of the benzene ring
would be different, which would result in two peaks
around 7.27 ppm (the standard chemical shift of
benzene ring) in the 1H NMR spectrum. Therefore, in
this study, the peaks at 6.768 ppm (signal a) and
7.091 ppm (signal b) in Fig. 3d signified the successful
conjugation of TAT peptide onto MWCNTs-PEG-Mal
[30].
As a model anticancer drug, DOX has been shown to
be able to be adsorbed onto the sidewalls of CNTs due
to their high surface area and conjugation structure via
π-π stacking [6]. Furthermore, the hydrophilicity behav-
ior of DOX is pH-dependent, which would be beneficial
for the π-π stacking between DOX and MWCNTs. Con-
sequently, the UV-Vis absorption spectroscopy results
indicated the successful loading of DOX on MWCNTs-
PEG and MWCNTs-PEG-TAT, and the high drug-loading
efficiency of the nanocarriers was due to the aromatic
structure and ultrahigh surface areas of MWCNTs.
The physicochemical characteristics are crucial factors
to the therapeutic performance of nanocarriers in drug
Fig. 7 Light microscopy images of MG63 and HUVEC cells treated with MWCNTs-PEG or MWCNTs-PEG-TAT for 24 h at MWCNTs concentration
of 50 μg/ml
Fig. 8 Viability of a MG63 cells and b HUVEC cells treated with MWCNTs-PEG and MWCNTs-PEG-TAT at different concentrations for 24 h
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delivery systems. The particle size would be a prerequisite
since it influences drug efficacy and pharmacokinetics
[31]. The size between 100 and 200 nm was demonstrated
to be the best size for enhanced permeability and reten-
tion (EPR) effect [32]. In this study, the average particle
size of DOX-MWCNTs-PEG and DOX-MWCNTs-PEG-
TAT were both perfectly controlled between 100 and
200 nm. Moreover, as electric charges repel each other,
potentials on surface of the nanoparticles can prevent
them from flocculation and keep them stable. There-
fore, zeta potential was measured to verify the stability
of the nanocarries. In our case, the modified MWCNTs
were all slightly negatively charged (Table 1), which
would be beneficial to their physical stability. As a result,
the appropriate particle size and excellent stability sug-
gested that DOX-MWCNTs-PEG and DOX-MWCNTs-
PEG-TAT would be suitable for drug delivery.
For drug delivery applications, the conjugated DOX
on nanocarries should be able to be released to exert its
therapeutic efficacy. As expected, the release profile of
DOX from MWCNTs complexes should also be pH-
dependent. This pH-triggered DOX release was attributed
to the increased hydrophilicity and higher solubility of
DOX at lower pH, which would be helpful to overcome
the π-π stacking between the DOX and MWCNTs com-
plexes and thus facilitates the detachment of DOX from
the nanotubes [30]. As a result, this particular release pro-
file would be beneficial for drug delivery applications,
since DOX would be released more in acidic tumor sites
than in the normal tissues, which could increase intercel-
lular distribution of DOX in tumor cells and benefit the
anticancer efficacy of MWCNTs nanocarriers [33].
The intracellular tracking of free DOX, DOX-MWCNTs-
PEG, and DOX-MWCNTs-PEG-TAT in MG63 and
Fig. 9 Viability of MG63 cells treated with free DOX, DOX-MWCNTs-PEG,
and DOX-MWCNTs-PEG-TAT for 24 h
Fig. 10 Fluorescence images of MG63 cells treated with DOX-MWCNTs-PEG-TAT at DOX concentration of 10 μg/ml for a 2 h, b 8 h, c 24 h,
and d 72 h
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HUVEC cells reflected the disparate mechanisms by
which they gained cellular entry (Fig. 6). Free DOX could
easily enter into cells and access the cell nucleus via
passive diffusion [34], while DOX-MWCNTs-PEG and
DOX-MWCNTs-PEG-TAT relied on an active transport
mechanism for cellular entry and then released the
drug in the cytoplasm and diffused into nuclei [35].
Moreover, the obviously higher red fluorescence distribu-
tion in DOX-MWCNTs-PEG-TAT than that of DOX-
MWCNTs-PEG clearly indicated the improved efficacy of
the former. There may be many reasons lying behind
this phenomenon. (1) The TAT peptide enhanced the
translocation across the cellular membrane. (2) The
TAT-mediated cytoplasmic uptake of drug conjugates
can deliver the cargo directly at periphery of the nu-
cleus and undergo endosomal escape [36], which would
increase the cytosolic drug concentration. (3) The TAT
peptide was reported to possess DNA-binding abilities
[37]. Therefore, the improved nuclear translocation
evidenced by the high nuclear accumulation of DOX-
MWCNTs-PEG-TAT in the MG63 and HUVEC cells
suggested that TAT may serve as a synergistic factor
for DNA targeting.
When compared with free DOX, the DOX-loaded
MWCNTs-PEG and MWCNTs-PEG-TAT both showed
a lower cytotoxicity at different concentrations (Fig. 9),
which was consistent with other studies of DOX bound
to nanocarries [26, 38]. This phenomenon could be
explained by the reason that free DOX was a hydro-
philic anticancer drug and could be quickly taken up
by passive diffusion and translocate to the nucleus to act
as a DNA intercalator and inhibitor of topoisomerase II
[39]. However, drug molecules conjugated on MWCNTs
released only after encountering lower pH inside cells and
so smaller amounts of drug could reach the nucleus to
exert a cytotoxic effect. Moreover, the cell vitality further
decreased with increasing of concentration, suggesting
that sufficient DOX was released from the DOX-loaded
nanotubes and was translocated into nuclei during the
incubation time.
However, unlike the DOX-MWCNTs-PEG which did
not result in appreciable cytotoxicity at the adminis-
tered concentrations, DOX-MWCNTs-PEG-TAT exhib-
ited much higher cytotoxicity and was even comparable
to free DOX especially at relatively high doses, indicat-
ing that the antiproliferative effect of the drug-loaded
MWCNTs was significantly increased by the modification
of TAT. It was probably because that upon endocytosis,
low endosomal pH could trigger the TAT insertion into
the endosomal membrane and facilitate its translocation
Fig. 11 Flow cytometric analysis of cell apoptosis using Annexin V-FITC and PI staining. The MG63 cells were treated with DOX-MWCNTs-PEG-TAT
at DOX concentration of 10 μg/ml for a 2 h, b 8 h, c 24 h, and d 72 h
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to the cytosol, which could increase the cytosolic concen-
tration of TAT modified drug nanocarriers [36]. Further-
more, the nuclear translocation capability of TAT peptide
[40] might also contribute to the improved anticancer effi-
cacy of DOX-MWCNTs-PEG-TAT since DOX is a DNA
interacting drug and causes cell apoptosis by damaging
the DNA structure [41].
Moreover, based on the in vitro cytotoxicity and
apoptosis assays, it could be demonstrated that the
DOX-MWCNTs-PEG-TAT could result in obvious anti-
proliferative and apoptosis effects to cancer cells. There-
fore, it was believed that the conjugation of TAT on
MWCNTs composites may potentially improve the thera-
peutic efficacy in anticancer research.
Consequently, these results indicated that, like free
DOX, the DOX-MWCNTs-PEG-TAT could efficiently
kill cancer cells via the induction of cell apoptosis. Fur-
thermore, the therapeutic efficacy of DOX was not com-
promised after being conjugated with MWCNTs-PEG-
TAT, which means that DOX can be released efficiently
from the internalized nanocarriers in the cytoplasmic
region and enters the nucleus to induce cell death when
encountered in intracellular endosome of low pH.
Conclusions
In conclusion, a highly effective drug delivery system
based on cell-penetrating peptide TAT modified with
PEGylated MWCNTs was developed, characterized,
and applied to augment the antitumor activity of DOX
to cancer cells. The results showed that the TAT-modified
MWCNTs displayed appropriate characteristics of nano-
sized drug carriers and showed potentiated anticancer effi-
cacy than non-TAT-modified MWCNTs. However, TAT
peptide is a non-specific ligand, which could penetrate
any cell and limits its applications especially in targeted
drug delivery. Therefore, improvements could be made by
grafting additional targeting ligand for their targeting to
defined cell compartments. Despite this, the results in the
present paper suggested that the unique combination of
TATand MWCNTs as a multifunctional drug delivery sys-
tem is potent in regressing tumor growth and might be a
powerful tool for improved anticancer drug development.
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